European VitreoRetinal Society a certain philosophy

Poster Gavin Tan Introduction: Choroidal neovascularization (CNV) is rare but important cause of visual impairment in children. It is often idiopathic or secondary to inflammation, optic nerve head abnormalities or retinal dystrophies. There is a lack of clinical trials assessing the treatment of CNV in children. Methods: A 11-year-old boy with no past medical or ocular history presented with 3 months duration of reduced vision in his...

Poster V. Levent Karabas Purpose: To evaluate the efficacy of intravitreal triamcinolone acetonite (IVT) injection versus intravitreal bevacizumab (IVB) injection in the management of subretinal fluid in patients with diabetic retinopathy. Methods: Forty-seven patient affected by diabetic macular edema with subretinal fluid were included. Patients were assigned randomly to two groups. IVT group, patients who received 4mg/0.1ml...

Poster 2 Osman Cekic To measure retinal vessel diameters following intravitreal bevacizumab injection in eyes with diabetic macular oedema.

Advantage: This paper aims to describe retinal changes during Spectral Domain Optical Coherence Tomography (SD-OCT) guided Bevacizumab treatment for neovascular age- related macular degeneration (AMD). Material and Methods: 47 eyes of 45 patients with wet AMD treated on demand with Bevacizumab. We used 3-dimensional SD-OCT to measure photoreceptor defects and subretinal fibrosis. The main efficacy endpoints were the SD-OCT measurements...

Purpose: The purpose of this study was to determine the appropriate timing of pars plana vitrectomy after pretreatment with intravitreal bevacizumab (IVB) for proliferative diabetic retinopathy using histopathological examination of epiretinal membrane biopsies. Material & Methods: This prospective study was conducted in Maghrabi Eye Hospital & Kuwait University Hospital, Sana, between January 2009 – May 2010. Forty...

The introduction of Intraocular Anti-VEGFs agents have significantly improved the management of a wide variety of neovscular ocular diseases including retinopathy of prematurity (ROP). In our hands, monotherapy treatment with intravitreal bevacizumab (IVB) is a favourable treatment modality in management of threshold ROP. In eyes with iris rubeosis, rigid pupils and vitreous haze where it is difficult to visualize the fundus and perform...

Advantages: Intravitreal bevacizumab followed by laser micropulse in CSME offers a clear advantage of non-inducing a visible retinal burn and having a potential efficiency in reducing foveal thickness and visual acuity Methods: Prospective case series. One hundred and twenty cases of non-ischemic non-tractional CSME with macular thickness more than 400 microns as defined by OCT were managed by initial intravitreal bevacizumab injection...

Purpose: To know the clinical outcomes of intravitreal bevacizumab with laser photocoagulation as primary treatment in the diabetic macular edema. Methods: Patients who diagnosed with DME without vitreomacular traction and not underwent any other treatment were choosen to receive an intravitreal bevacizumab injection alone in 30 eyes and an intravitreal bevacizumab injection with laser photocoagulation in 31 eyes. We compared both groups....

Purpose: To report the efficacy of a single intravitreal bevacizumab injection alone or in combination with intravitreal triamcinolone acetonide versus macular laser photocoagulation as primary treatment of diabetic macular edema. Methods:   72 eyes of 40 patients with clinically significant DME and no previous treatment were enrolled. The eyes were randomly assigned to one of three study arms: the intravitreal bevacizumab (IVB) group,...

Advantages: To evaluate visual and anatomical outcomes of macular edema (ME) secondary to central retinal vein occlusion (CRVO) after early onset treatment with intravitreal injections of bevacizumab (IVB). Methods: Ten consecutive eyes with ME secondary to nonischemic CRVO were included in this retrospective study. All patients had fundus fluorescein angiography (FFA) and optical coherence tomography at presentation. All patients were...

Satyen Deka, H Bhattacharjee, H Deka, M J Barman, S M Das (Guwahati, India) Advantages: Currently the only treatment option for exudative RD in nanophthalmic eye is surgical (Scleral Resection) with guarded visual prognosis. Intravitreal bevacizumab is a less invasive and safe treatment used for multiple retinal vascular/inflammatory diseases to treat the macular edema, the mode of action of which is through blockage of VEGF mediated...

Satyen Deka, H Bhattacharjee, H Deka, M J Barman, R Saibum, S M Das (Guwahati, India) Advantages: Preoperative intravitreal bevacizumab in diabetic tractional retinal detachment (TRD) facilitates surgery, decreases the intraoperative bleeding and improves the visual acuity. Methods: In this non comparative interventional case series 10 eyes of 8 candidate diabetic TRD patients received 1.25 mg intravitreal off level bevacizumab 2-7 days...

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Gungor Sobaci, Cuneyt Erdurman, A. Hakan Durukan (Ankara, Turkey) Purpose: Controversy exists in the literature regarding the most appropriate method of treatment in diabetic macular edema. We aimed to find out the current best care for selected group of patients who had untreated, acute, and diffuse diabetic macular edema. Methods: Patients with acute...

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Siamak Moradian, Amir Faramarz, Qiumars Heidari, Masoud Salehipoor, Mohammad Mohammadzadeh (Tehran, Iran) Advantages: To compare the results of IVT vs IVB vs sham injections at the end of phacoemulsification (PE) on diabetic macular edema (DME). Methods: In a RCT 88 diabetic patients with at least moderate NPDR were undergone one of the 3 injections, IVT...

http://www.evrs.eu/medias/2010/congress/Non-Proliferative-Diabetic-Maculopathies.flv Veronika Aslanova, Nikolai Umanets (Odessa, Ukraine) Advantages: Intravitreal bevacizumab injection lead to a significant visual improvement in patients with diabetic macular edema soon after procedure. Methods: 28 patients (36 eyes), (24 females, 4 males), mean age 62 y/o, with diabetic macular edema were consecutively enrolled in the noncomparative...

Yong Sung You, Oh Kwon (Seoul, South Korea) Purpose: To compare the efficacy of Avastina and Lucentis in Neovascular AMD of Korean in South Korea. Materials and Methods: Retrospective, comparative study by reviewing the medical records of patients with wet AMD who were treated with anti-VEGF and followed up more than 6 months from January 2007 to November 2009. Results: 105 eyes (105 patients) were included. Avastin was injected in 32 eyes...

Sung Pyo Park (Seoul, South Korea), Jae Kyoun Ahn (Gwangiu, South Korea) Purpose: To evaluate the therapeutic efficacy of intravitreal bevacizumab (IVB) in the treatment of branch retinal vein occlusion (BRVO) in eyes with normal tension glaucoma (NTG). Methods: We included sixteen NTG eyes and 48 age- and sex-matched eyes without NTG that had received IVB for BRVO with more than 6 months’ follow-up. The main outcome measures were...

http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv Ivan Fiser, Martina Rubesova (Prague, Czech Republic) Advantages: In most cases of persisting CME after BRVO we use vitrectomy with ILM peeling which has a good effect in more than 60 % of eyes but. In some patients we start with Avastin that brings a repeated benefit but later recurrences of CME happen. Laser coagulation in edematous...

Dae Young Lee, Suk Ho Moon, Sang Woong Moon, Dong Heun Nam, Hae Jung Paik (Incheon, South Korea) Advantages: To report the unwanted effects after intravitreal Bevacizumab injection as an adjunctive treatment to Panretinal Photocoagulation (PRP) for high-risk Proliferative Diabetic Retinopathy (PDR). Methods: The study was a retrospective chart review of patients with unwanted adverse effects (TRD, vitreous hemorrhage) following...

Ivan Fiser, Martina Rubesova (Prague, Czech Republic) Advantages: CME after CRVO is a typical case where it is very difficult to define which treatment is best to start with. Triamcinolone can be helpful (which was shown in a recent study) but a recurrence can happen. Avastin also has a temporary effect. ILM peeling can be beneficial, too, but we also see recurrences of CME after it. Laser treatment of edematous retina is difficult. We...

http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv Theodoros Potamitis, Yianna Antoniou (Limassol, Cyprus) Advantages: The use of Avastin has revolutionized the management of many retinal vasculopathies over the past few years and when its use leads to the avoidance of surgery the advantages to the patient are obvious. Methods: Patients over a five-year period with CRVO treated by both...

http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv Alireza Ramezani, Morteza Entezari, Siamak Moradian, Hamed Esfandiari, Babak Dehsarvi, Masoud Soheilian, Hamid Ahmadieh, Mehdi Yaseri (Tehran, Iran) Advantages: Repeated intravitreal injections of bevacizumab (IVB) are more effective than repeated intravitreal injections of triamcinolone (IVT) in acute retinal vein occlusion...

http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv Siamak Moradian, Hooshang Faghihi, Babak Sadeghi, Niloofar Piri, Hamid Ahmadieh, Masoud Soheilian, Mohammad Hossein Dehghan, Mohsen Azarmina, Mohammad Riazi Esfahani (Tehran, Iran) Advantages: To compare the visual and anatomical (central macular thickness; CMT) outcomes of intravitreal bevacizumab (IVB) injections relative to sham...

http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv Salim Ben Yahia, Riadh Messaoud, Imen Chtioui, Rim Kahloun, Sonia Zaouali, Moncef Khairallah (Monastir, Tunisia) Advantages: To manage macular edema secondary to retinal vein occlusion with intravitreal injection of bevacizumab. Methods: Thirty eyes of 30 patients with macular edema secondary to retinal vein occlusion (central retinal...

Montserrat González-Sastre, Ignasi Jurgens, Rosa Sust-Ferrer (Barcelona, Spain) Purpose: To report the 2-year visual and anatomical outcomes in patients treated with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD) in patients who failed after photodynamic therapy (PDT) or were not eligible to that treatment. Methods: Prospective, nonrandomized, open-label study of 114 eyes of 88 patients with AMD. We...

Kubilhan Elmas, Özgür Bilen, Ali Altýnsoy (Ankara, Turkey) Purpose: To describe the efficacy of intravitreal bevacizumab (Avastin) in patients with cystoid macular edema (CME) after cataract surgery (Irvine-Gass syndrome). Methods: This retrospective case series comprised 8 eyes of 8 patients with CME after cataract surgery refractory to current standard treatment that received an injection of 1.25 mg intravitreal Avastin. The main...

Kubilhan Elmas, Özgür Bilen, Ali Altýnsoy (Ankara, Turkey) Purpose: To evaluate the efficacy of intravitreal triamcinolone injection in eyes with macular edema due to branch retinal vein occlusion (BRVO) over a 1-year period. Methods: The authors performed a retrospective chart review of 18 eyes of 18 patients (mean age 71 years) who underwent intravitreal injections with 2 mg triamcinolone acetonide and 1,25 mg bevacizumab for macular...

http://www.evrs.eu/medias/2010/congress/Central-Serous-Chorioretinopathy.flv Ron A. Adelman, Shelly T. Lee (New Haven, FL, USA) Advantages: Intravitreal injection of bevacizumab may be effective in patients with recurrent central serous chorioretinopathy (CSC). Methods: A retrospective study of patients with a diagnosis of recurrent CSC who were treated with intravitreal bevacizumab from January 2007 – January 2009. 1.5 mg...

Osman Çekiç, M. Selim Kocabora, Nilay Kandemir (Istanbul, Turkey) Advantages: To assess the effectiveness of intravitreal triamcinolone and combined triamcinolone-bevacizumab injection as adjunctive treatment to grid laser for diffuse diabetic macular edema. Methods: Sixty-nine eyes of 69 patients (29 male, 40 female) with diffuse diabetic macular edema were intravitreally injected either with 4mg/0.1ml triamcinolone (n = 29) or...

Ozgür Bilen, Kubilhan Elmas, Ali Altýnsoy (Ankara, Turkey) Purpose: The aim of this study was to assess the efficacy of phacoemulsification combined with intravitreal bevacizumab injection in diabetics with clinically significant macular edema (CSME) and cataract. Methods: This retrospective study included diabetic patients with cataract and CSME who underwent phacoemulsification and intraocular lens implantation with a 1,25-mg...

Salim Ben Yahia, Rim Kahloun, Salma Gargouri, Rim Ghrissi, Riadh Messaoud, Moncef Khairallah (Monastir, Tunisia) Advantages: To manage choroidal neovascularization (CNV) secondary to angioid streaks with intravitreal injection of bevacizumab. Methods: Eight eyes of 8 patients with CNV secondary to angioid streaks were treated with intravitreal injection of 1.25 mg (0.05 mL) of bevacizumab. Main outcome measures included changes in...

Salim Ben Yahia, Bechir Jelliti, Rim Kahloun, Rim Ghrissi, Salah Jenzeri, Moncef Khairallah (Monastir, Tunisia) Advantages: To manage inflammatory choroidal neovascularization (CNV) with intravitreal injection of bevacizumab, since conventional therapeutic options, including laser photocoagulation, surgery, corticosteroids, and verteporfin therapy, have potential limitations and are associated with a high rate of recurrences. Methods:...

Nabil Abdulghani Taresh Ali, Amin A. Okbah, Ahmed Labib, Basma Alrefaei (Sanaa, Yemen) Purpose: To detect the role of intravitreal Avastin injection before pars plana vitrectomy in diabetic patients and when doing operation after Avastin injection. Material and methods: 40 patients with advanced proliferative diabetic retinopathy with tractional retinal detachment (TRD) and vitreous hemorrhage. Best corrected visual acuity Slit lamp...

http://www.evrs.eu/medias/2010/congress/Non-Age-Related-Macular-Degeneration-Nor-Diabetes-Neovascularization.flv Katia Papastavrou, Theodoros Potamitis, Maria Staktopoullou (Limassol, Cyprus) Advantages: Neovascularization of the anterior segment and anterior chamber angle is a devastating complication of many retinal vasculopathies. The use of intravitreal bevacizumab is minimally invasive and it is very effective in controlling...

http://www.evrs.eu/medias/2010/congress/Non-Age-Related-Macular-Degeneration-Nor-Diabetes-Neovascularization.flv Barbara Parolini, Grazia Pertile (Verona, Italy) Advantages: The results of our study would advise an on-demand intravitreal injection of bevacizumab (IVB) for juxtafoveal and a monthly scheme for subfoveal myopic choroidal neovascularization (CNV). Methods: We retrospectively analyzed the charts of 45 patients with myopic CNV...

http://www.evrs.eu/medias/2010/congress/Non-Age-Related-Macular-Degeneration-Nor-Diabetes-Neovascularization.flv Andriy Sergienko, Lyubomyr Lytvynchuk (Kyiv, Ukraine) Advantages: Intravitreal bevacizumab (Avastin) is a new and safe surgical treatment for choroidal neovascularization due pathologic myopia (myopic CNV). It allows controlling CNV activity and does not lead to development of foveal chorioretinal atrophy. In some cases, it...

http://www.evrs.eu/medias/2010/congress/Non-Age-Related-Macular-Degeneration-Nor-Diabetes-Neovascularization.flv Shree Kurup (Winston Salem, NC, USA), Ahmad Mansour (Lebanon), J. Arevalo (Venezuela) Advantages: Inflammatory choroidal neovascularization (CNV) is a potentially blinding complication in uveitis. In patients already on immunosuppressive, intraocular medications are reasonable options without increasing systemic...

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration-2.flv Slawomir Cisiecki (Lodz, Poland), Maciej Bednarski (Lodz, Poland), Michael Koss (Frankfurt am Main, Germany), Janusz Michalewski (Lodz, Poland) Advantages: The aim of combined treatment in cases of exudative ARMD is to reduce the rate of anti-VEGF injections. Core vitrectomy using intrector is indicated when there is no response after three monthly intravitreal...

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Ivan Fiser, Frantisek Benda (Prague, Czech Republic) Advantages: Therapy with Avastin, fully tailored to the finding, can reduce the number of injections. The “saturation phase” of the traditional treatment scheme consisting of three monthly injections is not necessary in all cases. We always adapt the treatment to the course of the disease and keep the...

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Janusz Michalewski, Slawomir Cisiecki, Krzysztof Dziegielewski, Zbigniew Pikulski, Dominik Odrobina, Jerzy Nawrocki (Lodz, Poland) Advantages: To describe and analyze morphological changes in the retina of patients treated on demand with intravitreal bevacizumab for more than 18 months. Methods: Patients with exudative AMD were treated when activity of CNV in...

http://www.evrs.eu/medias/2010/videos/SooGeunJoe_VP6_768K.flv Soo Geun Joe, Jong Uk Hwang, Joo Yong Lee, June-Gone Kim (Seoul, South Korea) Advantages: The authors will discuss their successful management of massive suprachoroidal hemorrhage with secondary angle closure glaucoma, which developed after photodynamic therapy (PDT) combined with intravitreal bevacizumab injection (IVB) for age-related macular degeneration (ARMD). In this...

[fhttp://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Ihor Novytskyy, Tetiana Smal, Markijan Novytskyy (Lviv, Ukraine) Advantages: Intravitreal administration of Avastin for exudative ARMD is cheap, effective and safe procedure. Methods: We have observed 147 patients (243 eyes) with wet ARMD, 68 females and 79 males, mean age 68 (52 to 87) years. 1 or 2 injections of Avastin were administered to 99 patients (168...

http://www.evrs.eu/medias/2010/videos/AhmedIbrahim_1_VP6_768K.flv Ahmed Ibrahim (Jeddah, Saudi Arabia) Advantages: Intravitreal Avastin Injection one Week prior to Vitrectomy and Removal of Advanced Diabetic Tractional Membrane Make It Easy to Sissect, Peel and Bleeding is less. Methods: Intravitreal Avastin injection done. And after one week 20 Gage pars plana vitrectomy performed with use of 23 Gauge curved needle and scissors to peel,...

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Sengul C. Ozdek, Sibel Eryigit, Berati Hasanreisoglu (Ankara, Turkey) Purpose: To determine if PRN Bevacizumab can maintain the visual acuity (VA) gained with loading Ranibizumab for wet ARMD. Methods: The reports of patients with wet ARMD treated with 3 monthly Ranibizumab followed by PRN Bevacizumab were reviewed retrospectively. VA and central foveal thickness...

http://www.evrs.eu/medias/2010/congress/Age-Related-Macular-Degeneration.flv Biljana Rascanin Draganic, Miroslav Vukosavljevic (Belgrade, Serbia) Advantages: Treating patients with wet AMD in a cost-effective way. Methods: 47 patients with wet AMD (diagnosed with fluorescein angiography-FA and optical coherent tomography-OCT) were given 3 monthly doses of 1.25 mg Avastin intravitreally, and were retreated as needed. All the patients were...

http://www.evrs.eu/medias/2010/congress/Proliferative-Diabetic-Retinopathy.flv Hassan Mortada (Cairo, Egypt) Advantages: Preoperative intravitreal Avastin injection produces significant reduction of retinal neovascularization. This dramatic effect may be related to its activity against all isoforms of VEGF. However, intravitreal Avastin injection is not without complications. It may lead to contraction of the fibrovascular tissue with...

http://www.evrs.eu/medias/2010/congress/Proliferative-Diabetic-Retinopathy.flv Arwa Azmeh, Wafi Maihoub (Damascus, Syria) Advantages: To evaluate the efficacy of intravitreal Bevacizumab  (IVB) injection in causing regression of new vessels activity in patients with proliferative diabetic retinopathy (PDR) refractory to pan retinal photocoagulation (PRP). Methods: 32 eyes of 23 patients with type 2 diabetes and active PDR refractory to...

http://www.evrs.eu/medias/2010/congress/Proliferative-Diabetic-Retinopathy.flv Mario R. Romano, C. Costagliola, P. Vinciguerra (Milan, Italy) Advantages: Intravitreal Bevacizumab is efficacious as pre-operative adjuvant treatment rather than intra-operative, for the management of recurrent postoperative hemorrhages in patients with advanced proliferative diabetic retinopathy (PDR). Methods: The patients were divided in two groups: Group A...

http://www.evrs.eu/medias/2010/congress/Vascular-Pathologies-in-Young-Patients.flv Barbara Parolini, Grazia Pertile (Verona, Italy) A 14-year-old boy came to our attention in August 2008 for vision loss in the left eye. Since January 2008, his left eye had progressivery lost vision to 0,1 Snellen BCVA. He presented with a massive submacular exudation due to vascular abnormalities located in the temporal quadrant. A choroido-retinal...

http://www.evrs.eu/medias/2010/congress/Vascular-Pathologies-in-Young-Patients.flv Ahmed El Khashab (Cairo, Egypt) Purpose: To report a retrospective, consecutive, non-comparative case series of progressive threshold stage 3 retinopathy of prematurity (ROP) treated by the conventional peripheral laser therapy together with intravitreal injection of bevacizumab (Avastin). Methods: The study included 25 eyes of 13 patients with progressive...

http://www.evrs.eu/medias/2010/congress/Vascular-Pathologies-in-Young-Patients.flv Ihab Saad Othman, Mohamed Sabry, Hany ELMekawy, Hisham Hosny (Giza, Egypt) Advantages: Threshold zone 1 and 2 ROP is a progressive disease with vision threatening complications. In this cohort, we could achieve retinal stabilization when 0.06 mg / 0.05 ml injection was performed 3-4 days prior to retinal ablation. Methods: Fourteen eyes received intravitreal...

http://www.evrs.eu/medias/2008/congress/Combined-Photodynamic-Therapy-with-Intravitreal-Bevacizumab-for-Neovascular-ARMD.flv Young Ju Lew, Moon Jung Choi, Tae Gon Lee, Sung Won Cho, (Kim,’s Eye Hospital, Konyang Universtiy, Seoul, Korea ), Eun Jee Chung (NHIC, Ilsan Hospital, Gyunggido, Korea), Sung Woo Ha (Bungdang CHA General Hospital, Pochun CHA University, Guyunggido, Korea) Advantages: To investigate the efficacy of combined...

http://www.evrs.eu/medias/2008/congress/Combined-Bevacizumab-and-Photodynamic-Theraphy-in-ARMD.flv V. Levent Karabaþ, Berna Özkan, Özgül Altýntaþ, Nurþen Yüksel, Yusuf Çaðlar Advantages: Combination of bevacizumab with PDT led to decreased need for recurrent injections of bevacizumab. Methods: The records of 62 patients who had combined bevacizumab injection and PDT for Age Related Macular Degeneration between March 2006 and...

Masih Hashemi, Roshanak Aliakbar Navahi, Khalil Ghasemi Falavarjani Advantages: In this double-blind randomized clinical trial study, we compared safety and effectiveness of intravitreal Triamcinolone Acetonide (TA) versus Avastin in patients with Clinically Significant Macular Edema (CSME). Methods: Four mg TA was injected in 28 eyes and 1.25 mg Avastin was injected in 23 eyes of patients with CSME. The visual acuity, intraocular pressure,...

Masood Naseripour, Mohammad Reza Oladi, Khalil Ghasemi Falavarjani, Hossein Nazari Advantages: We describe the electrophysiologic changes in G-ERG recordings of subjects who were treated with 1.25 or 2.5 mg of intravitreal bevacizumab for treatment of CNV associated with AMD. Methods: In this prospective comparative interventional study, 23 patients with active choroidal neovascularization (CNV) associated with AMD were enrolled. Patients...

Hee Yoon Cho, Byung Ro Lee (Hanyang University College of Medicine, Seoul, Korea Advantages: Intravitreal injection of Avastin® (bevacizumab) as adjuvant premedication before cataract surgery on patients with diabetic retinopathy (DR) is expected to reduce the risk of DR progression and aggravation of diabetic macular edema during immediately postoperative period and to additionally enhance visual improvement. Methods: A prospective...

Osman Cekic, Mehmet Cakir, Cengiz Alagoz, Nese Alagoz, Omer F. Yilmaz Advantages: To demonstrate the effectiveness of triple therapy in patients with subfoveal choroidal neovascular membrane (SCNM) related to age-related macular degeneration (AMD). Methods: Twenty-nine eyes of 26 patients (10 male, 16 female, mean age: 71.2 years) with SCNM that underwent triple therapy were evaluated retrospectively. Intravitreal injection of 2 mg...

Bikbov M.M., Altynbaev U.R. Purpose: To study anatomic and functional findings of 25G vitrectomy combined with preoperative intravitreally injected Avastin in patients with active form of proliferative diabetic retinopathy (PDR). Material & Methods: 9 patients (10 eyes) with PDR accompanied with expressed retinal neovascularization were included into investigation. Tractional retinal detachment was found in 8 cases, tractional and...

Morteza Entezari, Alireza Ramezani, Ladan Safavizadeh, Nader Bassirnia (Ophthalmic Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran) Advantages: To report a successful treatment of a severe exudative maculapathy in a 13-year-old boy with Coat’s disease by three intravitreal bevacizumab injections. Conventionally, laser photocoagulation and cryotherapy have been used for treatment of Coat’s disease;...

Díez Villalba, Rosario, Mora de Oñate Javier, Rodriguez Márquez, María Trinidad, Izquierdo Vázquez Cristina, Alvarez Holgado Marta, Hita Antón César We present four cases of cystoid macular edema (CME) secondary to retinal telangiectasia: 1 case of Coats disease (adult form), 2 cases of unilateral macular telangiectasia (type 1) and 1 case of bilateral macular telangiectasia (type 2). Three cases were treated with intravitreal...

Ben Yahia S, Jenzeri S, Hmidi K, Attia S, Zaouali S, Khairallah M Purpose: To compare response after intravitreal bevacizumab (IVB) or triamcinolone (IVT) in diabetic macular edema with severe hard exudates. Methods: Forty-eight eyes were randomly assigned to either IVB or IVT. Follow-up was > 6 months. Results: There was significant improvement in BCVA in the IVT group when compared with the IVB group (P= .04). Complete resolution of...

Ben Yahia S, Herbort CP, Zaouali S, Ammari W, Jelliti B, Messaoud R, Khairallah M Background: Treatment modalities for choroidal neovascularization due to ocular toxoplasmosis include laser photocoagulation, surgery, corticosteroids, and verteporfin therapy. Intravitreal injection of bevacizumab in the treatment of choroidal neovascularization due to other conditions appears to be an effective and safe therapeutic option. Case Reports: We...

Hulya Gungel, Deniz Oygar Baylancicek, Isil Basgil, Nihat Sayin, Eylem Yaman Pinarci Purpose: To evaluate the anatomic and visual outcomes of 23-gauge transconjunctival sutureless vitrectomy for a variety of vitreoretinal conditions in patients with diabetic retinopathy. Methods: A retrospective, consecutive, interventional case series for 21 eyes of 20 patients with proliferative diabetic retinopathy. Patients underwent vitreoretinal...

http://www.evrs.eu/medias/2008/congress/Combined-Intravitreal-Bevacizumab-and-Triamcinolone-Acetonide-for-the-Treatment-of-Acute-Non-Arteritic-Anterior-Ischemic-Optic%20Neuropathy.flv Morteza Entezari, Alireza Ramezani, Hassan Ghassemi, Alireza Naderi Ophthalmic Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran. Purpose: To report the effect of combined intravitreal bevacizumab and triamcinolone acetonide...

http://www.evrs.eu/medias/2008/congress/Intravitreal-Bevacizumab-in-Retinopathy-of-Prematurity:-30-Months-Follow-Up.-Will-we-Change-our-Way-of-Treating-ROP.flv Maria Ana Martinez-Castellanos, Jose Luis Guerrero-Naranjo, J. Gerardo Garcia-Aguirre, Virgilio Morales-Canton, Omar Honerlage-Merino, R.V. Paul Chan, Hugo Quiroz-Mercado Advantages: We present a treatment with antiangiogenic therapy for retinopathy of prematurity with good outcome...

http://www.evrs.eu/medias/2008/congress/The-Role-of-Anti-Vascular-Endothelial-Growth-Factor-(VEGF)-Therapy-(Bevacizumab)-in-the-Management-of-Retinopathy-of-Prematurity.flv Ehab N El Rayes Advantages: To evaluate the possible role of using Anti VEGF therapy (Bevacizumab ) in treating retinopathy of prematurity (ROP). Methods: 38 eyes of infants with ROP received Anti VEGF (Bevacizumab) 1.25 mg / 0.05 ml for varying stages of ROP. Group 1...

http://www.evrs.eu/medias/2008/congress/Effects-of-Bevacizumab-on-Diabetic-Macular-Edema-in-Proliferative-Diabetic-Retinopathy.flv Lala Ceklic (University Eye Clinic Kasindo, Eastern Sarajevo, Bosnia and Herzegovina), Slobodanka Latinovic (University Eye Clinic of Novi Sad, Novi Sad, Vojvodina-Serbia) Advantages: The non-selective anti vascular endothelial growth factor antibody (VEGF) bevacizumab (Avastin) has been used for the treatment...

A. Barak, Z. Burgansky-Eliash, D. Nelson, O. Pupko, M. Berkowitch, A. Lowenstein, A.Grinvald Advantages: The Retinal Function Imager (RFI) implements a new, non-invasive diagnostic approach to measure blood flow velocity. Intravitreal Bevacizumab is widely used for treatment of various retinal conditions. We used the RFI to learn about the drug’s effect on retinal vascular function. Methods: This pilot study includes seven patients who...

http://www.evrs.eu/medias/2008/congress/Tailored-Therapy-with-Avastin-Helps-Patients-with-AMD-to-Save-Money.flv Ivan Fiser, Nikola Toskova, Cornea Lexum Eye Clinic, Prague, Czech Republic Advantages: For senior patients even the cheapest therapy with three monthly injections of Avastin, followed with three-month check-ups, can exceed their financial limits. The tailored therapy, based on the application of a single injection, followed by a...

Guy l’Helgoualch, MD (Brest, France) PURPOSE: To check using Avastin in intravitreous injection reduces the surface and the thickness of the neovascular membrane. To check improving the effect of PDT and reducing the side effects increases the final visual acuity. To verify this protocol of tritherapy reduces the number of treatment during the period of follow-up. METHODS: The population of patients includes the same proportion of...

Myriam Lucia Hernandez-Rojas, MD (Mexico City, Jose Dalma- Weiszhausz, MD (MexicoCity, Mexico), Hugo Quiroz- Mercado, MD (Mexico City, Mexico), Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Maura Abraham-Marin, MD (Mexico City, Mexico), Adriana Solis-Vivanco, MD (Mexico City, Mexico), Elizabeth Reyna-Castelan, MD (Mexico City, Mexico), Jose Luis Guerrero-Naranjo,MD (Mexico City,...

Michael A. Singer, MD (San Antonio, TX), Rafael Lin Wong, (San Antonio, TX), Catherine Alderete, CMA (San Antonio, TX), Robin Hartman, BBA (San Antonio, TX) PURPOSE: To determine whether combination therapy of Avastin and Kenalog is useful in the treatment of corneal neovascularization. METHODS: A patient presenting with severe corneal neovascularization in both eyes and Hand Motion (HM) vision was given multiple treatments of Avastin, by...

Naomi S. Falk, MD (Albany, NY), Paul M. Beer, MD (Albany, NY), Amjad M. Hammad, MD (Albany, NY) PURPOSE: To explore contrast between objective improvement and visual function. METHODS: Study design is a case report of a 55 year old woman who received 2 injections of intravitreal Bevacizumab for Adult Vitelliform dystrophy due to complaints of blurred vision and distortion. She had received 4 prior injections of Pegaptanib sodium without...

Ubeyt Inan Umit, MD (Ayfon, Turkey), Tuncay Kusbeci, MD (Afyon, Turkey), Berkant Kaderli (Bursa, Turkey), Remzi Avci, MD (Bursa, Turkey), Umit Kaplan, MD (Afyon, Turkey), Faruk Ozturk, MD (Turkey) PURPOSE: Intravitreal bevacizumab, a recombinant humanized monoclonal antibody directed against VEGF, has been increasingly used for treatment of age-related macular degeneration, PDR and macular edema due to retinal vein occlusions. We reported...

Panos Stergiou, (Thessaloniki, Greece), Kostantinos Malamos, MD (Thessaloniki, Greece), Efstathios Dragiotis, MD (Thessaloniki, Greece), Anastasios Felekidis, MD (Thessaloniki, Greece), Tania Karagiani, MD (Thessaloniki, Greece), Stavros Dimitrakos, MD (Thessaloniki, Greece) PURPOSE: To investigate whether combined intravitreal use of triamcinolone (Kenacort) and bevacizumab (Avastin) can prolong the beneficial effect and reduce the need...

Joerg C. Schmidt, MD (Marburg, Germany), Stefan Mennel, MD (Marburg, Germany), Carsten Meyer, PD, MD (Marburg, Germany), Stefan Hoerle, MD (Marburg, Germany) PURPOSE: Subretinal CNV extraction and macular transposition can be offered to selected patients as a treatment option. When this surgery was first used, the development of PVR was the main postoperative complication, now CNV recurrence is the major problem. METHODS: During the last...

Arturo Santos, MD, PhD (Guadalajara, Mexico), Enrique A. Roig-Melo, MD PhD (Guadalajara, Mexico), Ramon Flores-Fuentes, MD (Guadalajara, Mexico), Juan C. Altamirano, MD (Guadalajara, Mexico) PURPOSE: To evaluate the feasibility and safety of the combination of photodynamic therapy with verteporfin (PDT), intravitreal Bevacizumab and preservative free Triamcinolone acetonide (PFTA) for the treatment of exudative AMD. METHODS: This is a...

Frank H.J. Koch, MD (Frankfurt am Main, Germany),* Albert J. Augustin, MD (Karlsruhe, Germany), Robert G. Josephberg, MD (Yonkers, NY),* K. Peter Luloh, (Sanford, FL),* Indre Offermann, MD (Karlsruhe, Germany), Shahrzad Ghozisad, MD (Frankfurt am Main, Germany), Joachim Puchta, MD (Frankfurt am Main,Germany), Pankaj Singh, MD (Frankfurt Am Main, Germany) PURPOSE: A treatment regimen that combines photodynamic therapy (PDT) with a core pars...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Enhanced-Pegaptanib-(Macugen)-Therapy-for-Choroidal-Neovascularization-in-AMD:-An Avastin-Booster.swf Michael J. Tolentino, MD (Winter Haven, FL),* David M. Misch, MD (Winter Haven, FL), Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, Fl) PURPOSE: The study purpose is to determine if bevacizumab combined with pegaptanib can harness the rapid...

http://www.evrs.eu/medias/2006/congress/Combination-Avastin-and-Reduced-Fluence-Photodynamic-Therapy-for-Choroidal-Neovascularization.swf David Callanan, MD (Arlington, TX),* Wayne Solley, MD (Arlington, TX) PURPOSE: The purpose of the study is to determine whether the combination of intravitreal Avastin and reduced fluence PDT is as effective as either treatment alone; and whether the combination therapy may reduce the number of treatments...

Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Elizabeth Reyna-Castelán, MD (Mexico City, Mexico), Juan Manuel Jimenez- Sierra, MD (Mexico City, Mexico), Adriana Solis-Vivanco, MD (Mexico City, Mexico), Jose Luis Guerrero-Naranjo, MD (Mexico City, Mexico), Maura Abraham-Marin, MD (Mexico City, Mexico), Myriam Lucia Hernández-Rojas, MD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Maria Ana Martinez-...

Gaurav K. Shah, MD (St. Louis, MO), Mandeep S. Dhalla, MD (St. Louis, MO), Kevin J. Blinder, MD (St. Louis, MO), Edwin H. Ryan, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Asheesh Tewari, MD (St. Louis, MO) PURPOSE: To examine the 6-month results of a group of patients treated with combined photodynamic therapy (PDT) with verteporfin with intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to...

http://www.evrs.eu/medias/2006/congress/Combination-Therapy-for-Wet-Age-related-Macular-Degeneration-Using-Verteporfin-Photodynamic-Therapy-and-Intravitreal-Bevacizumab.swf Jose Dalma-Weiszhausz, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Ana Suarez- Lincona, MD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Orlando Ustariz...

Jose Luis Rosales Meneses, MD, PhD (San Cristobal, Venezuela), Pedro P. Bonomo de Oliveira, MD (Sao Paulo, Brazil), Liz J. Florez Ovalles, MD (San Cristobal, Venezuela) PURPOSE: To evaluate the short term safety of systemic bevacizumab (Avastin) and its effects on visual acuity and subfoveal choroidal neovascularization in patients with neovascular age related macular degeneration. METHODS: Open label, single center, uncontrolled clinical...

Derek L. Barker, MD (Tallahassee, FL), H. Logan Brooks, MD (Tallahassee, FL), Robert L. Steinmetz, MD (Tallahassee, FL), Charles K. Newell, MD (Tallahassee, FL), Carmen A. Puliafito, MD (Miami, FL), Philip J. Rosenfeld, MD, PhD (Miami, FL) PURPOSE: Is bevacizumab more effective at preventing vision loss from juxtafoveal macular degeneration than photodynamic therapy? METHODS: A six month retrospective analysis of patients with juxtafoveal...

Alex Melamud, MD (Durham, NC), Sharon Fekrat, MD (Durham, NC),* Jeff Taylor, MD (Raleigh, NC), Sandra S. Stinnett, PhD (Durham, NC) PURPOSE: Do 3 consecutive monthly injections of intravitreal bevacizumab (Avastin®) produce a sustained clinical improvement in eyes with neovascular agerelated macular degeneration? METHODS: We performed a retrospective review of consecutive eyes with all choroidal neovascular lesion subtypes due to...

Paul E. Tornambe, MD (Poway, CA)* PURPOSE: There are concerns that pan VEGF suppression may negatively effect the retinal and choroidal vasculature. The purpose of this paper is to describe what effect pulsed pan-VEGF inhibition using intravitreal Avastin has upon the retinal and choroidal vasculature and the six month response of the sub foveal choroidal neovascular membrane to intravitreal Avastin injections? METHODS: Thirty consecutive...

http://www.evrs.eu/medias/2006/congress/Time to Recurrence of AMD-related CNV Leakage after a Single Initial-Intravitreous-Injection-Bevacizumab-(Avastin):-Implications-for-a-Retreatment.swf Edgar L. Thomas, MD (Beverly Hills, CA)* PURPOSE: To evaluate the time to recurrent leakage on optical coherence tomography after a single initial intravitreous injection of bevacizumab (Avastin) for CNV in AMD METHODS: This is a retrospective chart...

Ahmad M. Mansour, MD (Beirut, Lebanon), Ziad Bashshur, MD (Beirut, Lebanon), Isam Hamade, MD (Beirut, Lebanon) PURPOSE: We investigated the safety of a combination therapy (phacoemulsification with intravitreal avastin) for an optimal visual recovery. METHODS: The study is a prospective review of consecutive patients treated by 2 surgeons at one medical center from January 2006 to March 2006. Intravitreal avastin (0.1ml) was injected at...

J. Fernando Arevalo, MD, FACS (Caracas, Venezuela), Lihteh Wu, MD (San Jose, Costa Rica), Juan G. Sanchez, MD (Caracas, Venezuela), Mauricio Maia, MD (Sao Paulo, Brazil), Mario J. Saravia, MD (Buenos Aires, Argentina) PURPOSE: To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR). METHODS: Retrospective study of patients with RN due to PDR who...

Charles E. Lyon, MD (Shreveport, LA), David H Ren, MD, PhD (Shreveport, LA) PURPOSE: To investigate the visual outcome of intravitreal bevacizumab in treating subfoveal choroidal neovascularization due to age-retlated macular degeneration. METHODS: An open label, nonrandomized, prospective observational study was done on patients with subfoveal choroidal neovascularization due to AMD regardless of lesion type and previous treatment. After...

Timothy W. Olsen, MD (Minneapolis, MN),* Xiao Feng, MD (Minneapolis, MN),* Kathy Wabner, BA (Minneapolis, MN),* Stanley R. Conston, BS (Menlo Park, CA),* David H. Sierra, PhD (Menlo Park, CA),* Tom S. Chang, MD (Pasadena, CA),* Karl G. Csaky, MD PhD (Bethesda, MD), Morton E. Smith, MD (St. Louis, MO), J. Douglas Cameron, MD (Rochester, MN) PURPOSE: To describe a drug delivery system, surgical technique, safety and pharmacokinetics for...

Swati Agarwal, MD (Jacksonville, FL), Sandeep Grover, MD (Jacksonville, FL), K.V. Chalam, MD, PhD (Jacksonville, FL), Sweta Tarigopula, MD (Jacksonville, FL), Shailesh Kumar Gupta, MD (Jacksonville, FL) PURPOSE: To report the efficacy of intracameral Bevacizumab (anti VEGF agent) in the treatment of neovascularization of the iris. METHODS: 3 eyes with severe neovascularization of the iris, secondary to proliferative diabetic retinopathy...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Treatment-of-Choroidal-Neovascularization-Secondary-to-Age-related-Macular-Degeneration.swf Richard F. Spaide, MD (New York, NY),* Ketan Laud, MD (New York, NY), Howard Fine, MD (New York, NY), James M. Klancnik, MD (New York, NY), Catherine Meyerle, MD (New York, NY), Lawrence Yannuzzi, MD (New York, NY), John Alan Sorenson, MD (New York, NY), Jason S. Slakter, MD...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-for-Primary-Treatment-of-Neovascular-AMD.swf David F. Williams, MD, MBA (Minneapolis, MN), Steven R. Bennett, MD (Minneapolis, MN), Herbert L. Cantrill, MD (Minneapolis, MN), Jill B. Johnson, MD (Minneapolis, MN), Robert A. Mittra, MD (Minneapolis, MN), Robert C. Ramsay, MD (Minneapolis, MN), Edwin H. Ryan, MD (Minneapolis, MN), Sundeep Dev, MD (Minneapolis,...

Alessandro A. Castellarin, MD (Santa Barbara, CA), Robert L. Avery, MD (Santa Barbara, CA),* Dante J. Pieramici, MD (Santa Barbara, CA),* Ma-an A. Nasir, MD (Santa Barbara, CA), Melvin D. Rabena, BS (Santa Barbara, CA), Matthew J. Giust, CRA (Santa Barbara, CA) PURPOSE: To report the safety and biologic effect of intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration in patients followed for a minimum of 6...

Ubeyt Inan Umit, MD (Ayfon, Turkey), Berrin Avci, MD (Bursa, Turkey), Tuncay Kusbeci, MD (Afyon, Turkey), Berkant Kaderli (Bursa, Turkey), Remzi Avci, MD (Bursa, Turkey) PURPOSE: Choroidal neovascular membrane, proliferative retinopaties and retinal vascular occlusions are caused by microvascular disability stimulated mainly with vascular endothelial growth factor (VEGF). Bevacizumab, as a full-length anti-VEGF, has been one of the...

http://www.evrs.eu/medias/2006/congress/Injection-of-Intravitreal-Avastin-Before-Vitrectomy-Surgery-in-the-Treatment-of-Severe-Proliferative-Diabetic-Retinopathy.swf http://www.evrs.eu/medias/2006/congress/Injection-of-Intravitreal-Avastin-Before-Vitrectomy-Surgery-in-the-Treatment-of-Severe-Proliferative-Diabetic-Retinopathy.flv Stanislao Rizzo, MD (Pisa, Italy), Federica Genovesi-Ebert, MD (Pisa, Italy), Emanuele Di Bartolo, MD (Pisa,...

David Hauser, MD (Kefar Bilu B, Israel), Yoel Greenvald, MD (Rehovot, Israel), Amir Bukelman, MD (Rehovot, Israel), Haya Katz, MD (Rehovot, Israel), Reut Parnes, MD (Rehovot, Israel), Nir Shoham, (Rehovot, Israel), Genady Landa, MD (Rehovot, Israel), Ayala Pollack, MD (Rehovot, Israel) PURPOSE: To compare the outcome of intravitreal triamcinolone (Kenalog) and intravitreal bevacizumab (Avastin) for eyes with serous PED and occult choroidal...

http://www.evrs.eu/medias/2006/congress/Primary-Intravitreal-Bevacizumab-(Avastin)-for-the-Treatment-of-CNV-Secondary-to-AMD:-Results-of-the-Pan-American-Collaborative-Retina-Study-Group.swf Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), J. Fernando Arevalo, MD, FACS (Caracas, Venezuela), Hugo Quiroz-Mercado, MD (Mexico City, Mexico), Juan G. Sanchez, MD (Caracas, Venezuela), Lihteh Wu, MD (San Jose, Costa Rica), Jose Dalma-Weiszhausz,...